Monitoring patients with uveal melanoma for liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with uveal melanoma who are at high risk for metastatic relapse. It involves a tailored follow-up approach that includes regular liver MRI scans and blood tests to identify biomarkers for early diagnosis of liver metastases. Patients will undergo imaging assessments every six months for at least five years, and blood samples will be collected to support biomarker research. The study aims to enhance oncological surveillance based on individual risk factors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient aged of 18 years or more.
2. Patient with uveal melanoma with high metastatic relapse risk defined as :

   * T2b/c/d ou ≥ T3,
   * or chromosom 3 or chromosom 8 abnormality by CGH array.
3. Completion of treatment of the primary tumor ≤ 2 months.
4. Patient able to comply with the schedule of visits and blood samples of the study.
5. Signed informed consent form or legal representative.

Exclusion Criteria:

1. Patient without french social insurance.
2. Any social, medical or psychological condition making the research process impossible.

Where it's running

• Institut Curie
  Paris, France Recruiting

Study contacts

• Principal investigator: Sophie Piperno-Neumann, MD — Institut Curie
• Study coordinator: Sophie Piperno-Neumann, MD
• Email: sophie.piperno-neumann@curie.fr
• Phone: 01 44 32 46 72

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-precision radiosurgery followed by minimally invasive eye-sparing surgery for prominent uveal melanoma

  This study tests a modern, precise radiosurgery approach followed by a minimally invasive surgery to see if it can control the tumor while preserving vision in patients with high-prominence uveal melanoma.

  Recruiting at 3 sites University Hospital, Essen · Essen, Germany / NRW and 2 other locations · NCT07913412

• Adjuvant darovasertib and crizotinib in high-risk non-metastatic uveal melanoma

  Researchers are testing whether adding darovasertib and crizotinib after local eye tumor treatment can help prevent recurrence in people with high-risk, non-metastatic uveal melanoma.

  Recruiting at 4 sites Phase 3 IDEAYA Biosciences · Scottsdale, Arizona and 12 other locations · NCT07804186

• Neoadjuvant immunotherapy for high-risk eye melanoma

  This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07501117

• Immune response after delivering melphalan directly to the liver for uveal (eye) melanoma that has spread to the liver.

  This test will see how the liver's immune system responds when people with uveal melanoma that has spread to the liver receive melphalan delivered directly to the liver through percutaneous hepatic perfusion.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07364474

• Adding IL-2 to tebentafusp to overcome resistance in uveal melanoma

  This trial tests whether giving interleukin‑2 (IL‑2) together with tebentafusp can help people with HLA‑A*02:01 metastatic uveal melanoma who progressed on tebentafusp.

  Recruiting Phase 1/2 St Vincent's Hospital, Sydney · Sydney, New South Wales and 1 other locations · NCT07063875

• Darovasertib before local treatment for primary uveal melanoma

  This trial tests whether giving darovasertib before surgery or radiation helps people with primary non-metastatic uveal melanoma.

  Recruiting at 25 sites Phase 3 IDEAYA Biosciences · Scottsdale, Arizona and 93 other locations · NCT07015190

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.